RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy.
C. Denkert
Stock Ownership - Sividon Diagnostics
R. Kronenwett
Employment or Leadership Position - Sividon Diagnostics
Stock Ownership - Sividon Diagnostics
S. Loibl
No relevant relationships to disclose
V. Nekljudova
No relevant relationships to disclose
S. Darb-Esfahani
No relevant relationships to disclose
B. Gerber
No relevant relationships to disclose
B. Sinn
No relevant relationships to disclose
C. Petry
Employment or Leadership Position - Sividon Diagnostics
Stock Ownership - Sividon Diagnostics
I. Bauerfeind
No relevant relationships to disclose
J. Budczies
No relevant relationships to disclose
M. Rezai
No relevant relationships to disclose
M. Dietel
Stock Ownership - Sividon Diagnostics
I. Schrader
No relevant relationships to disclose
G. Kunz
No relevant relationships to disclose
G. Von Minckwitz
No relevant relationships to disclose